Two of the cases with CREBBP::GOLGA6L2 and CREBBP::LCMT1 fusions fulfilled the molecular criteria for GBM, IDH wildtype including + 7/-10 signature and homozygous deletion of CDKN2A/B as well as IDH wildtype status. This evidence concerns the gene CDKN2A and glioblastoma.